

Antonio DomÃ- nguez Meijide

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6542469/publications.pdf>

Version: 2024-02-01

22
papers

1,003
citations

516710

16
h-index

677142

22
g-index

25
all docs

25
docs citations

25
times ranked

1585
citing authors

#	ARTICLE	IF	CITATIONS
1	Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. <i>Neurobiology of Disease</i> , 2012, 47, 268-279.	4.4	91
2	Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models. <i>Molecular Neurobiology</i> , 2018, 55, 7297-7316.	4.0	79
3	Spreading of α -Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 107.	2.9	79
4	Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1337-1342.	3.9	77
5	Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 277-290.	4.1	77
6	Aging-related dysregulation of dopamine and angiotensin receptor interaction. <i>Neurobiology of Aging</i> , 2014, 35, 1726-1738.	3.1	75
7	Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 58, 209-219.	4.4	62
8	Synucleinopathies: Where we are and where we need to go. <i>Journal of Neurochemistry</i> , 2020, 153, 433-454.	3.9	62
9	Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1 β . <i>Experimental Neurology</i> , 2014, 261, 720-732.	4.1	57
10	Cytosolic Trapping of a Mitochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies. <i>Cell Reports</i> , 2019, 28, 65-77.e6.	6.4	41
11	Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA. <i>Neuropharmacology</i> , 2014, 76, 156-168.	4.1	40
12	Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells. <i>Experimental Neurology</i> , 2013, 250, 384-396.	4.1	39
13	Rho Kinase and Dopaminergic Degeneration. <i>Neuroscientist</i> , 2015, 21, 616-629.	3.5	39
14	Doxycycline inhibits α -synuclein-associated pathologies in vitro and in vivo. <i>Neurobiology of Disease</i> , 2021, 151, 105256.	4.4	35
15	Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. <i>Age</i> , 2013, 35, 1675-1690.	3.0	32
16	Effects of pharmacological modulators of α -synuclein and tau aggregation and internalization. <i>Scientific Reports</i> , 2020, 10, 12827.	3.3	29
17	Synthesis and evaluation of esterified Hsp70 agonists in cellular models of protein aggregation and folding. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 79-91.	3.0	17
18	Pharmacological Modulators of Tau Aggregation and Spreading. <i>Brain Sciences</i> , 2020, 10, 858.	2.3	17

#	ARTICLE	IF	CITATIONS
19	LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?. <i>Biochemical Society Transactions</i> , 2019, 47, 827-838.	3.4	15
20	Aging-Related Overactivity of the Angiotensin/AT1 Axis Decreases Sirtuin 3 Levels in the Substantia Nigra, Which Induces Vulnerability to Oxidative Stress and Neurodegeneration. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 416-424.	3.6	14
21	Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 635760.	3.4	14
22	Aging-related dysregulation in enteric dopamine and angiotensin system interactions: implications for gastrointestinal dysfunction in the elderly. <i>Oncotarget</i> , 2018, 9, 10834-10846.	1.8	11